中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

28 records (took 0.027 seconds)

    Marker for statin treatment stratification in heart failure
    21.
    发明授权
    Marker for statin treatment stratification in heart failure 有权

    公开(公告)号：US10234464B2

    公开(公告)日：2019-03-19

    申请号：US15054255

    申请日：2016-02-26

    Applicant: Roche Diagnostics Operations, Inc.

    Inventor： Dirk Block ,  Hans-Peter Brunner ,  Thomas Dieterle ,  Ursula-Henrike Wienhues-Thelen ,  Christian Zaugg ,  Andre Ziegler

    IPC: G01N33/50 ,  G01N33/68 ,  A61K31/40 ,  G01N33/62

    Abstract: The present invention is directed to a method of identifying a patient having heart failure as likely to respond to a therapy comprising a statin. The method is based on measuring the level of at least one marker selected from GDF-15 (Growth Differentiation Factor 15), Urea, SHBG (Sex Hormone-Binding Globulin), Uric acid, PLGF (Placental Growth Factor), IL-6 (Interleukin-6), Transferrin, a cardiac Troponin, sFlt-1 (Soluble fms-like tyrosine kinase-1), Prealbumin, Ferritin, Osteopontin, sST2 (soluble ST2), and hsCRP (high sensitivity C-reactive protein) in a sample from a patient. Further envisaged is a method of predicting the risk of a patient to suffer from death or hospitalization, wherein said patient has heart failure and undergoes a therapy comprising a statin. The method is also based on the measurement of the level of at least one of the aforementioned markers.

    TnT BASED DIAGNOSIS OF PAROXYSMAL ATRIAL FIBRILLATION
    25.
    发明申请
    TnT BASED DIAGNOSIS OF PAROXYSMAL ATRIAL FIBRILLATION 审中-公开
    基于TnT的PAROXYSMAL ATRIAL FIBRILLATION的诊断

    公开(公告)号：US20170074892A1

    公开(公告)日：2017-03-16

    申请号：US15359674

    申请日：2016-11-23

    Applicant: Roche Diagnostics Operations, Inc.

    Inventor： Dirk Block ,  Roberto Latini ,  Serge Masson ,  Ursula-Henrike Wienhues-Thelen ,  Christian Zaugg ,  Andre Ziegler

    IPC: G01N33/68

    CPC classification number: G01N33/6887 ,  G01N33/6869 ,  G01N33/6893 ,  G01N2333/4712 ,  G01N2333/4737 ,  G01N2333/4745 ,  G01N2333/5412 ,  G01N2333/58 ,  G01N2800/326 ,  G01N2800/52

    Abstract: The present invention relates to a method for diagnosing a recent paroxysmal atrial fibrillation. The method is based on the determination of the at least one marker selected from the group consisting of a cardiac Troponin, NT-proBNP (N-terminal prohormone of brain natriuretic peptide), hsCRP, IL-6 (Interleukin-6) and IGFBP7 (Insulin like growth factor binding protein 7) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). Further, the present invention relates to a method for identifying a subject being treatable with anticoagulation therapy. Further envisaged are systems, reagents and kits used in performing the methods disclosed herein.

    Abstract translation: 本发明涉及一种诊断近期阵发性房颤的方法。 该方法基于选自心肌肌钙蛋白，NT-proBNP（脑钠尿肽的N-末端激素原），hsCRP，IL-6（白细胞介素-6）和IGFBP7（ 来自受试者的样品中的胰岛素样生长因子结合蛋白7），以及由此确定的量与参考量（参考量）的比较。 此外，本发明涉及用抗凝治疗来鉴别受治疗者的方法。 进一步设想的是用于执行本文公开的方法的系统，试剂和试剂盒。

    IGFBP7 FOR DIAGNOSING DIASTOLIC DYSFUNCTION
    26.
    发明申请
    IGFBP7 FOR DIAGNOSING DIASTOLIC DYSFUNCTION 审中-公开
    IGFBP7用于诊断软组织损伤

    公开(公告)号：US20170010283A1

    公开(公告)日：2017-01-12

    申请号：US15274533

    申请日：2016-09-23

    Applicant: Roche Diagnostics Operations, Inc.

    Inventor： Johann Karl ,  Ursula-Henrike Wienhues-Thelen ,  Dirk Block ,  Christian Zaugg ,  Hans-Peter Brunner ,  James Januzzi ,  Andre Ziegler ,  Julian Braz ,  Thomas Dieterle ,  Edelgard Kaiser

    IPC: G01N33/68

    CPC classification number: G01N33/6893 ,  G01N33/6887 ,  G01N2333/47 ,  G01N2800/325

    Abstract: The present invention relates to a method for diagnosing and/or grading diastolic dysfunction or at least one structural or functional abnormality associated with diastolic dysfunction. The method comprises measuring the level of IGFBP7 (Insulin like growth factor binding protein 7) and, optionally, the level of at least one further marker in a patient suffering from heart failure, and comparing the level to a reference level. Further envisaged is a method of monitoring diastolic function in a patient suffering from heart failure. Also encompassed by the present invention are kits and devices adapted to carry out the method of the present invention.

    Abstract translation: 本发明涉及一种用于诊断和/或分级舒张功能障碍或与舒张功能障碍相关的至少一种结构或功能异常的方法。 该方法包括测量患有心力衰竭的患者中IGFBP7（胰岛素样生长因子结合蛋白7）的水平和任选地至少一个其他标记物的水平，并将该水平与参考水平进行比较。 进一步设想的是监测患有心力衰竭的患者的舒张功能的方法。 本发明还包括适用于实施本发明方法的试剂盒和装置。

    NTproBNP AND cTnT BASED THERAPY GUIDANCE IN HEART FAILURE
    27.
    发明申请
    NTproBNP AND cTnT BASED THERAPY GUIDANCE IN HEART FAILURE 审中-公开
    NTproBNP和cTnT基于心理失常的治疗指导

    公开(公告)号：US20150233945A1

    公开(公告)日：2015-08-20

    申请号：US14705299

    申请日：2015-05-06

    Applicant: Roche Diagnostics Operations, Inc.

    Inventor： Dirk Block ,  Julian Braz ,  Hans-Peter Brunner ,  James Creeden ,  Hans-Juergen Loyda ,  Ursula-Henrike Wienhues-Thelen ,  Christian Zaugg

    IPC: G01N33/68

    CPC classification number: G01N33/6887 ,  G01N33/6893 ,  G01N2333/47 ,  G01N2333/58 ,  G01N2800/325 ,  G01N2800/52

    Abstract: The present invention relates to a method for guiding heart failure treatment in a subject suffering from heart failure. The method is based on the determination of the amount of a BNP-type peptide and a cardiac troponin in a sample from said subject. Further envisaged by the present invention are kits and devices adapted to carry out the present invention. The present invention also relates to a system for guiding heart failure treatment in a subject suffering from heart failure as disclosed herein and to reagents and kits used in performing the methods disclosed herein.

    Abstract translation: 本发明涉及一种在患有心力衰竭的受试者中引导心力衰竭治疗的方法。 该方法基于来自所述受试者的样品中BNP型肽和心肌肌钙蛋白的量的测定。 本发明进一步设想的是适用于实施本发明的试剂盒和装置。 本发明还涉及用于指导本文公开的患有心力衰竭的受试者的心力衰竭治疗的系统以及用于执行本文公开的方法的试剂和试剂盒。

    IDENTIFICATION OF PATIENTS WITH ABNORMAL FRACTIONAL SHORTENING
    28.
    发明申请
    IDENTIFICATION OF PATIENTS WITH ABNORMAL FRACTIONAL SHORTENING 审中-公开
    鉴别患有异常分娩的患者

    公开(公告)号：US20150185230A1

    公开(公告)日：2015-07-02

    申请号：US14644695

    申请日：2015-03-11

    Applicant: Roche Diagnostics Operations, Inc

    Inventor： Dirk Block ,  Roberto Latini ,  Serge Masson ,  Ursula-Henrike Wienhues-Thelen ,  Christian Zaugg

    IPC: G01N33/68 ,  A61B5/055 ,  A61B8/08

    CPC classification number: G01N33/6887 ,  A61B5/055 ,  A61B8/0883 ,  G01N33/82 ,  G01N2333/4703 ,  G01N2333/4706 ,  G01N2333/4712 ,  G01N2333/50 ,  G01N2333/78 ,  G01N2800/32 ,  G01N2800/329 ,  G01N2800/50

    Abstract: The present invention relates to a method for assessing whether a subject shall be subjected to an imaging based diagnostic assessment. The method is based on the determination of the amount(s) of a cardiac Troponin and/or Fibroblast Growth Factor 23 (FGF-23) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). The present invention also relates to a system for performing an assessment whether a subject shall be subjected to an imaging based diagnostic assessment and to reagents and kits used in performing the methods disclosed herein. Moreover, the present invention is directed to a method for predicting the risk of mortality and/or of a cardiovascular event. Also encompassed is a method for diagnosing an early stage of LVH in a subject having a preserved left ventricular ejection.

    Abstract translation: 本发明涉及一种用于评估受试者是否应进行基于成像的诊断评估的方法。 该方法基于来自受试者的样品中心肌肌钙蛋白和/或成纤维细胞生长因子23（FGF-23）的量的测定，以及因此确定的量（s） 具有参考量（参考量）。 本发明还涉及一种用于执行评估受试者是否应进行基于成像的诊断评估的系统以及用于执行本文所公开的方法的试剂和试剂盒。 此外，本发明涉及一种用于预测死亡风险和/或心血管事件风险的方法。 还包括用于诊断具有保留的左心室射血的受试者的LVH的早期阶段的方法。

Patent Agency Ranking